ALS (Lou Gehrig's)
No evidence cannabis slows ALS itself. Symptom trials are few; spasticity is the most promising target.
Neurology Emerging
What the research says
The honest headline: no trial has shown cannabis slows ALS progression. The evidence is entirely about symptoms, and it's thin — a 2022 review of the medical literature found just four clinical studies in ALS. The strongest signal is spasticity: one randomized, placebo-controlled trial of nabiximols (THC/CBD oromucosal spray) in 59 ALS patients found a significant reduction in ALS-related spasticity, and a retrospective cohort reported similar findings. THC as dronabinol, tested for cramps, showed no significant improvement in cramp intensity or quality of life in a 2010 crossover trial. A randomized trial of a high-CBD, low-THC oil (the EMERALD trial) is testing whether CBD affects disease progression — results are still pending.
Preclinical data (in ALS mouse models) does suggest neuroprotective potential, which drives ongoing trials — but animal results have repeatedly failed to translate in human ALS, so treat them as hypothesis only.
The honest caveats
This is a fragile patient population: swallowing and breathing problems matter, cognition can be affected, and drug interactions are real — smoked cannabis is especially unwise. If symptom relief (especially spasticity) is the goal, standardized THC/CBD products under a neurologist's supervision are the evidence-based option. No one should use cannabis hoping it will slow the disease — that is not supported by any human data.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.